Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 5/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.52 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.49 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | F10 | P00742 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11210548 | 0.88 | MEN1 (0.58) | HTTLMNATSHRHSD17B1HSD17B2 | |
| SCHEMBL1703738 | 0.86 | RAB9A (0.51) | HTTALDH1A1MAPTKDM4ESMN1; SMN2 | |
| SCHEMBL23507149 | 0.84 | ALDH1A1 (0.45) | HTTLMNATSHRALDH1A1MAPT | |
| SCHEMBL8318170 | 0.83 | ALDH1A1 (0.52) | HTTALDH1A1MAPTKDM4ESMN1; SMN2 | |
| SCHEMBL9097384 | 0.83 | ALDH1A1 (0.47) | HTTLMNATSHRALDH1A1MAPT | |
| SCHEMBL29083423 | 0.83 | RXFP1 (0.60) | HTTLMNATSHRHSD17B1HSD17B2 | |
| SCHEMBL22439046 | 0.83 | ALDH1A1 (0.47) | HTTALDH1A1MAPTKDM4ESMN1; SMN2 | |
| SCHEMBL30601564 | 0.83 | ALDH1A1 (0.47) | HTTALDH1A1MAPTKDM4ESMN1; SMN2 | |
| SCHEMBL11639863 | 0.82 | KMT2A (0.57) | HTTLMNATSHRALDH1A1MAPT | |
| SCHEMBL3044578 | 0.82 | KMT2A (0.53) | HTTLMNAALDH1A1KDM4EMTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260008792-A1 | PROCESSES AND COMPOUNDS | RADIUS PHARMACEUTICALS INC (US) | 2026-01-08 | — | — | US | disclosed |
| US-12441745-B2 | Processes and compounds | RADIUS PHARMACEUTICALS, INC. (US) | 2025-10-14 | — | — | US | disclosed |
| US-20250295798-A1 | LIGAND-DRUG CONJUGATE OF EXATECAN ANALOGUE, AND MEDICAL USE THEREOF | BEIGENE SWITZERLAND GMBH (CH) | 2025-09-25 | — | — | US | disclosed |
| EP-4594327-A1 | LIGAND-DRUG CONJUGATE OF EXATECAN ANALOGUE, AND MEDICAL USE THEREOF | BeiGene Switzerland GmbH (CH) | 2025-08-06 | — | — | EP | disclosed |
| CN-119948031-A | Ligand-drug conjugates of isatecan analogs and medical uses thereof | 广州百济神州生物制药有限公司 | 2025-05-06 | — | — | CN | disclosed |
| CN-119912339-A | In the ilast group Process for the preparation of intermediates | 浙江天宇药业股份有限公司 | 2025-05-02 | — | — | CN | disclosed |
| CN-119569588-A | Preparation method and intermediate of ilast hydrochloride | 杭州诺澳生物医药科技有限公司 | 2025-03-07 | — | — | CN | disclosed |
| CN-119390714-A | Methods and compounds | 雷迪厄斯制药公司 | 2025-02-07 | — | — | CN | disclosed |
| CN-119100936-A | In the ilast group Synthesis method of intermediate | 杭州诺澳生物医药科技有限公司 | 2024-12-10 | — | — | CN | disclosed |
| CN-113348163-B | Methods and compounds | 雷迪厄斯制药公司 | 2024-10-08 | — | — | CN | disclosed |
| US-20210155612-A1 | Alpha,Beta-UNSATURATED AMIDE COMPOUND | KYOWA KIRIN CO., LTD. (JP) | 2021-05-27 | — | — | US | disclosed |
| EP-3712129-A1 | ALPHA, BETA-UNSATURATED AMIDE COMPOUND | Kyowa Kirin Co., Ltd. (JP) | 2020-09-23 | — | — | EP | disclosed |
| WO-2020167855-A1 | PROCESSES AND COMPOUNDS | RADIUS PHARMACEUTICALS, INC. (US) | 2020-08-20 | — | — | WO | disclosed |
| CN-110770211-A | α unsaturated amide compound | 协和麒麟株式会社 | 2020-02-07 | — | — | CN | disclosed |
| CN-1058262-C | Novel 1-phenylalkanone 5-HT4Receptor ligands | SYNTEX INC (US) | 2000-11-08 | — | — | CN | disclosed |
| EP-0700383-B1 | NOVEL 1-PHENYLALKANONE 5-HT 4? RECEPTOR LIGANDS | SYNTEX INC (US) | 1998-09-23 | — | — | EP | disclosed |
| US-5763458-A | NERVOUS SYSTEM DISORDERS, ANXIETY, ANTIDEPRESSANTS AND COGNITION ACTIVATORS | SYNTEX (U.S.A.) INC. (US) | 1998-06-09 | — | — | US | disclosed |
| CN-1124485-A | Novel 1-phenylalkanone 5-HT4Receptor ligands | SYNTEX A INC (US) | 1996-06-12 | — | — | CN | disclosed |
| WO-1994027965-A1 | NOVEL 1-PHENYLALKANONE 5-HT4 RECEPTOR LIGANDS | SYNTEX (U.S.A.) INC. (US) | 1994-12-08 | — | — | WO | disclosed |
| US-4102924-A | REACTING ACYLAMINO-ARYLS WITH HALO-ARYLS | BAYER AKTIENGESELLSCHAFT (DE) | 1978-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210155612-A1 | Alpha,Beta-UNSATURATED AMIDE COMPOUND | NR1H2, NR1H3, RXRA | HTT 3570/4885LMNA 1763/4885TSHR 971/4885 |
| US-20250295798-A1 | LIGAND-DRUG CONJUGATE OF EXATECAN ANALOGUE, AND MEDICAL USE THEREOF | SLC10A1, ERBB3, SLC10A2 | HTT 2220/4885LMNA 1114/4885TSHR 409/4885 |
| US-12441745-B2 | Processes and compounds | ESR1, ESR2, CYP19A1 | HTT 4758/4885LMNA 2261/4885TSHR 450/4885 |
| US-20260008792-A1 | PROCESSES AND COMPOUNDS | ESR1, ESR2, PGR | HTT 4616/4885LMNA 1895/4885TSHR 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.